Augment Investments has announced its acquirement of an additional 10.032% stake in Pharmstandard OJSC, from Bristley Enterprises, to become a 79.8% stake holder in the company, upon the completion of the transaction.
Augment Investments has announced to acquire additional 10.032% stake in Pharmstandard OJSC, from Bristley Enterprises, to become a 79.8% stake holder in the company, upon the completion of the transaction.
According to the transaction, Augment will hold 15.2m global depository receipts (GDS) of Pharmstandard.
Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.
Excellence in Action YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.
